Phosphorus Binder with Dithiolane Carboxylate Salt
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phosphorus binders used in treating hyperphosphatemia, particularly in patients with chronic kidney disease, are ineffective in binding dietary phosphorus without causing significant adverse effects such as diarrhea, constipation, or gastric irritation, and often require high doses, which is costly and inconvenient.
Innovation Solution
A composition comprising a cationic phosphate binder, such as calcium or lanthanum salts, combined with a dithiolane carboxylate salt, particularly magnesium lipoate, which binds phosphorus in both hydrophilic and lipophilic environments, reducing absorption in the gastrointestinal tract and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional phosphorus binders (calcium salts, magnesium salts, aluminum salts) are used to bind dietary phosphorus, then phosphorus binding capacity is improved, but adverse effects (diarrhea, constipation, gastric irritation) worsen
Solution Approach 1:
The patent combines multiple binder materials (calcium carbonate, magnesium hydroxide, aluminum hydroxide) with dietary fibers (cellulose, hemicellulose, pectin) and binding agents (starch, gelatin) to create a composite phosphorus binder. This composite structure allows the different components to work synergistically: the metal salts provide phosphorus binding capacity while the dietary fibers and binding agents form a matrix that reduces direct contact with gastric contents and modulates release, thereby maintaining binding efficacy while reducing adverse effects like gastric irritation and gastrointestinal disturbances
2Quantity of substance
If high doses of phosphorus binders are administered to achieve effective phosphorus binding, then phosphorus binding capacity is improved, but cost and convenience worsen
Solution Approach 1:
The patent modifies the physical and chemical parameters of the phosphorus binder by incorporating dietary fibers and binding agents that alter the release characteristics and stability of the active binding components. This allows for more efficient phosphorus binding at lower doses by improving the bioavailability and targeted delivery of the binding agents to phosphorus in the gastrointestinal tract, thereby reducing the required dosage and improving cost-effectiveness and patient compliance
3Device complexity
If single-component phosphorus binders are used, then formulation simplicity is improved, but binding effectiveness in different gastrointestinal environments worsens
Solution Approach 1:
The patent creates a multi-component formulation where each ingredient serves a specific local function: calcium carbonate targets alkaline environments for phosphorus binding, magnesium hydroxide and aluminum hydroxide address acidic gastric environments, while dietary fibers provide structure and modulate release in different gastrointestinal regions. This localized optimization of binding capacity across different pH and environmental conditions throughout the GI tract enhances overall effectiveness without requiring a single complex material
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of cationic phosphate binders with dithiolane carboxylate salts effectively reduces serum phosphorus levels while minimizing adverse effects like diarrhea and constipation, allowing for lower doses and improved patient comfort and cost-effectiveness.
Implementation Method 1
a dithiolane carboxylate salt, particularly magnesium lipoate, which binds phosphorus in both hydrophilic and lipophilic environments
Implementation Method 2
Phosphorus binding is a chemical reaction between dietary phosphorus and a cation of the binder compound, resulting in the formation of insoluble and hence unabsorbable phosphate compounds
Data Source
AI summary
The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.